This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Haemolytic-uraemic syndrome비정형 용혈-요독증후군

ICD-10: D59.3 | Synonyms: Atypical HUS, aHUS, Atypical hemolytic uremic syndrome, complement-mediated thrombotic microangiopathy

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Early descriptions of hemolytic uremic syndrome

Hemolytic uremic syndrome (HUS) was recognized as a distinct disease in 1955, when Conrad von Gasser et al. first described the triad of acute hemolytic anemia, thrombocytopenia, and acute renal failure in 5 Swiss children. Initially all HUS was regarded as the same disease, but it was later shown that the clinical course differs greatly depending on the cause.

Establishing the concept of "atypical" HUS

During the 1980s–1990s, Shiga toxin produced by enterohemorrhagic Escherichia coli (E. coli O157:H7) was identified as the main cause of diarrhea-associated HUS in children. This led to the systematization of the concept of "atypical HUS (aHUS)", distinct from Shiga toxin-associated HUS (ST-HUS). aHUS is unrelated to Shiga toxin and is characteristically recurrent with a poor prognosis.

Linking complement abnormalities to aHUS

In 1998, Warwicker et al. first reported that variants in the complement regulatory protein factor H (complement factor H, CFH) are associated with familial aHUS. Throughout the 2000s, variants in factor I (CFI), MCP (CD46), factor B (CFB), C3, thrombomodulin (THBD), DGKE, and others were identified in aHUS patients, establishing aHUS as a disease caused by dysregulation of the alternative complement pathway.

Eculizumab and the treatment revolution

In 2011, the approval of eculizumab (a terminal complement inhibitor) by the US FDA for the treatment of aHUS shifted the treatment paradigm. Before eculizumab, more than 50% of aHUS patients progressed to end-stage renal disease or died, but eculizumab treatment has greatly improved the prognosis.

2. Causes

Complement dysregulation (genetic causes)

The most important cause of aHUS is genetic variants in regulatory proteins of the alternative complement pathway. Major causative genes: CFH (factor H, 40–45%), MCP/CD46 (10–15%), CFI (factor I, 5–10%), C3 (5–10%), CFB (factor B, 1–4%), THBD (thrombomodulin, 3–5%). The genetic variants are inherited in an autosomal dominant or recessive manner and show incomplete penetrance.

Autoantibody-mediated form

Anti-factor H autoantibodies (anti-CFH autoantibody) are found in 5–10% of aHUS patients. This occurs mainly in children and is associated with CFHR1-CFHR3 gene deletion. The autoantibodies block the complement regulatory function of factor H, causing complement overactivation.

Triggering factors

In individuals with genetic variants, infection (especially upper respiratory and gastrointestinal infection), pregnancy, surgery, drugs, hematopoietic stem cell transplantation, and other factors trigger the onset of aHUS. Infection or pregnancy promotes complement activation, pushing already unstable complement regulation beyond a critical threshold.

3. Genetics

Mode of inheritance and penetrance

Depending on the causative gene, aHUS is inherited in an autosomal dominant (CFH, CFI, C3, CFB, THBD) or autosomal recessive (some MCP/CD46 variants) manner. An important feature is incomplete penetrance: only some family members carrying the same variant develop clinical disease (penetrance 40–50%). This suggests the importance of environmental triggering factors.

Types of CFH variants and their clinical significance

Both loss-of-function and gain-of-function CFH variants are reported. Variants in the CFH C-terminal binding domain (SCR19-20) selectively impair only complement regulation on cell surfaces, so the protein is functionally defective even when serum CFH levels are normal, making diagnosis difficult.

Rearrangements of CFH-related protein (CFHR) genes

In the CFH gene cluster (1q31-32), the CFHR1–5 genes, which are structurally similar to CFH, lie adjacent to it. Unequal crossing over within this region can form a CFH-CFHR1 hybrid gene or produce a CFHR1-CFHR3 deletion, causing aHUS.

4. General epidemiology

Worldwide prevalence

The estimated incidence of aHUS is 0.5–2 per million population per year, making it an extremely rare disease. According to aHUS patient registry data from European countries, there are estimated to be about 3,000–5,000 patients worldwide.

Age and sex distribution

aHUS occurs in both children and adults. Pediatric onset (median age at first onset about 2 years) accounts for about 40–50% of all cases. Adult aHUS is somewhat more frequent in women, and pregnancy-associated aHUS occurs characteristically in women. A family history is reported in about 20–30%.

Status in Korea

In Korea, aHUS is an extremely rare disease, and national incidence data are limited. Since the 2010s, with the introduction of eculizumab in Korea, cases of systematic diagnosis and treatment of aHUS have begun to be reported. Patients are managed mainly at rare disease specialty centers in Korea and are registered in the Health Insurance Review & Assessment Service (HIRA) rare disease database.

5. Pathophysiology

Persistent activation of the alternative complement pathway

Normally, the complement alternative pathway is tightly regulated on cell surfaces by factor H, factor I, MCP, and others. In aHUS, loss-of-function variants in these regulatory proteins (or gain-of-function variants in factor B/C3) lead to persistent formation of C3 convertase on cell surfaces.

Development of thrombotic microangiopathy (TMA)

Persistent complement activation forms the terminal complement complex (MAC, membrane attack complex, C5b-9), causing direct damage to endothelial cells. In addition, the C5a anaphylatoxin activates endothelial cells and platelets. Activated endothelial cells oversecrete vWF and express tissue factor, so that platelet-fibrin thrombi form in arterioles and capillaries.

Mechanism of kidney injury

Glomerular capillaries are particularly vulnerable to complement attack because their endothelial cells are extensively exposed to blood flow. Intraglomerular thrombus formation, endothelial cell swelling, and platelet consumption lead to progressive acute renal failure. Besides the kidney, TMA can also occur in the vasculature of the brain, heart, intestine, and lungs.

6. Symptoms

Classic triad

The classic clinical triad of aHUS is ① microangiopathic hemolytic anemia (MAHA), ② thrombocytopenia, and ③ acute kidney injury. These three present together, and prodromal symptoms may include nausea, vomiting, fatigue, and pallor.

Extrarenal symptoms

Besides the kidney, aHUS can show multiorgan involvement, including the nervous system (stroke, seizures, impaired consciousness), heart (cardiomyopathy, heart failure), lungs (pulmonary edema), and gastrointestinal tract (abdominal pain, diarrhea, intestinal ischemia). Extrarenal symptoms are an indicator of poor prognosis.

Pregnancy-associated aHUS

Pregnancy or the postpartum period is a major trigger of aHUS. TMA develops during pregnancy or after delivery, and differentiation from preeclampsia or HELLP syndrome is important. Pregnancy-associated aHUS tends to persist postpartum, so close follow-up is needed.

7. Signs

Physical examination findings

Pallor (anemia), jaundice (hemolysis), oliguria or anuria, edema, and hypertension are the main physical signs. With nervous system involvement, decreased consciousness, seizures, and focal neurological deficits occur. When Budd-Chiari syndrome develops, abdominal distension, ascites, hepatomegaly, and abdominal tenderness may be observed.

Laboratory findings

Complete blood count (CBC): acute anemia with Hb 6–9 g/dL, platelets <100x10^9/L (often <50x10^9/L), normal white blood cell count. Blood smear: schistocytes observed (marker of microangiopathic hemolysis, 1% or more). Chemistry: rapidly rising creatinine (renal failure), markedly elevated LDH (marker of hemolysis), decreased or absent haptoglobin, elevated indirect bilirubin. Coagulation tests: PT/aPTT mostly normal. Complement tests: decreased serum C3 (about 60%), normal C4 (alternative pathway activation), measurement of CFH/CFI levels.

ADAMTS13 activity

When ADAMTS13 activity is severely reduced (<10%), the diagnosis is TTP (thrombotic thrombocytopenic purpura), differentiating it from aHUS. In aHUS, ADAMTS13 activity is normal or mildly reduced.

8. Screening

TMA diagnostic algorithm

When microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute kidney injury occur together, perform differential diagnostic testing for TMA immediately. Step 1: exclude ST-HUS (stool culture, stool Shiga toxin PCR), measure ADAMTS13 activity (to exclude TTP), and exclude causes of secondary TMA (drugs, autoimmune, transplant-related).

Tests for complement abnormalities

Measurement of serum C3, C4, CH50, and AH50. Measurement of serum CFH and CFI levels. Measurement of anti-CFH autoantibodies (anti-CFH antibody). Gene panel testing (analysis of CFH, CFI, MCP/CD46, C3, CFB, THBD, DGKE, and CFHR1-5 genes).

Renal biopsy

Renal biopsy is performed when renal failure persists or the diagnosis is unclear. It confirms the morphological findings of TMA (platelet-fibrin thrombi, endothelial cell swelling, glomerular ischemia) and excludes other causes (anti-GBM disease, ANCA vasculitis, etc.).

9. Diagnosis

Diagnostic criteria for aHUS

The diagnosis of aHUS is a diagnosis of exclusion based on integrating clinical and laboratory findings. Diagnostic criteria: ① MAHA (presence of schistocytes, elevated LDH, decreased haptoglobin, negative direct Coombs test), ② thrombocytopenia (<150x10^9/L), ③ acute kidney injury, ④ Shiga toxin negative, ⑤ ADAMTS13 activity >10% (TTP excluded), ⑥ causes of secondary TMA excluded.

Complement gene panel testing

Next-generation sequencing (NGS)-based panel testing including CFH, CFI, MCP/CD46, C3, CFB, THBD, DGKE, and CFHR1-5 is used for confirmation. A pathogenic variant is identified in about 60%, and the absence of a variant does not exclude clinical aHUS.

Differential diagnosis

ST-HUS (Shiga toxin-associated HUS): positive stool culture and toxin testing. TTP: ADAMTS13 activity <10%. Preeclampsia/HELLP syndrome: differentiated in pregnancy-associated TMA by clinical findings and response to delivery. Secondary TMA: drug-induced (quinine, sirolimus), autoimmune (SLE, antiphospholipid syndrome), transplant-associated TMA.

10. Treatment

Eculizumab

Eculizumab is a humanized monoclonal antibody that specifically inhibits the terminal complement component C5 and received FDA approval for aHUS in 2011. By inhibiting C5, it blocks C5a generation and MAC (C5b-9) formation, suppressing endothelial cell damage and platelet activation. Administration: an initial induction dose followed by maintenance doses given intravenously every 2 weeks. Eculizumab treatment leads to recovery of platelet counts, normalization of hemolysis markers, and recovery or stabilization of renal function.

Ravulizumab

Ravulizumab is an improved anti-C5 antibody derived from eculizumab; because of its long half-life, it is given every 8 weeks. It received FDA approval for aHUS in 2019 and is as effective as eculizumab while reducing dosing frequency, which can lower the treatment burden for patients.

Plasma exchange and immunosuppressive therapy

If the diagnosis is uncertain before eculizumab is given, plasma exchange or plasma infusion may be used concurrently. In patients with CFH deficiency, fresh frozen plasma may provide temporary CFH replacement. In anti-CFH autoantibody-positive aHUS, immunosuppressive therapy such as steroids, mycophenolate mofetil, and rituximab is combined.

Kidney transplantation

Kidney transplantation is needed in aHUS patients who have reached end-stage renal disease. Because patients with CFH, CFI, C3, or CFB variants have a high risk of aHUS recurrence after transplantation (50–100%), prophylactic eculizumab is strongly recommended before and after transplantation.

11. Prognosis

Prognosis before eculizumab

Before the introduction of eculizumab, the prognosis of aHUS was poor. More than 50% reached end-stage renal disease within 3–5 years of first presentation, and mortality exceeded 25%. Relapse occurred in 50–80%.

Prognosis after eculizumab

Eculizumab treatment rapidly suppresses TMA episodes and achieves long-term maintenance and recovery of renal function. Clinical trial data showed normalization of platelet counts and stabilization of renal function in more than 80% of eculizumab-treated patients. Early administration of eculizumab is key to improving prognosis.

Prognosis by variant type

CFH variants: very poor prognosis without treatment, marked improvement with eculizumab. MCP/CD46 variants: relatively good prognosis even without eculizumab; relapses are frequent, but spontaneous recovery is also possible. CFI variants: severe phenotype; eculizumab is effective, but recovery of renal function is incomplete in some patients.

12. Prevention

Meningococcal vaccination

Because eculizumab/ravulizumab inhibit terminal complement, the risk of infection with encapsulated bacteria (meningococcus, pneumococcus, Haemophilus) increases greatly. Meningococcal vaccination (ACWY and type B) at least 2 weeks before starting eculizumab treatment is mandatory. If treatment must be started in an emergency without vaccination, prophylactic antibiotics are given concurrently.

Eculizumab maintenance therapy to prevent relapse

Because the underlying complement abnormality in aHUS persists, eculizumab maintenance therapy is key to preventing relapse. Whether to continue or stop treatment is individualized according to variant type, clinical course, and renal function. With MCP/CD46 variants, relapse after stopping treatment is frequent, so long-term maintenance therapy is often needed.

Genetic counseling and family screening

Screen family members of aHUS patients for complement gene variants. For variant carriers, prepare early warning and prophylactic eculizumab plans for exposure to triggering factors (infection, pregnancy, surgery). Preconception genetic counseling is essential.

13. References

  1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676-1687.
  2. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181.
  3. Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681-696.
  4. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15-39.
  5. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998;53(4):836-844.
  6. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS. Clin J Am Soc Nephrol. 2010;5(10):1844-1859.
  7. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33(6):508-530.
  8. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267-1279.
  9. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11):643-657.
  10. Palma LM, Langman CB. Complement system in atypical hemolytic uremic syndrome. Pediatr Nephrol. 2021;36(12):3751-3771.
  11. Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy. Kidney Int. 2017;91(3):539-551.
  12. Nester CM, Barbour T, De Cordoba SR, et al. Atypical aHUS: state of the art. Mol Immunol. 2015;67(1):31-42.